AR075177A1 - Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros. - Google Patents

Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros.

Info

Publication number
AR075177A1
AR075177A1 ARP100100186A ARP100100186A AR075177A1 AR 075177 A1 AR075177 A1 AR 075177A1 AR P100100186 A ARP100100186 A AR P100100186A AR P100100186 A ARP100100186 A AR P100100186A AR 075177 A1 AR075177 A1 AR 075177A1
Authority
AR
Argentina
Prior art keywords
group
atom
cycloalkyl
absent
carbon
Prior art date
Application number
ARP100100186A
Other languages
English (en)
Inventor
Patrick Mougenot
Eric Nicolai
Claudie Namane
Christophe Philippo
Eykmar Fett
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42261833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0900359A external-priority patent/FR2941457A1/fr
Priority claimed from FR0904137A external-priority patent/FR2949464B1/fr
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR075177A1 publication Critical patent/AR075177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Reivindicacion 1: Compuesto que responde a la formula (1) en la que U representa un átomo de oxígeno o un átomo de nitrogeno, sabiendo que cuando U representa un átomo de oxígeno, entonces R5 está ausente; n es igual a 0, 1, 2 o 3; p es igual a 0, 1 o 2; D representa un átomo de oxígeno, un grupo -NH- o un enlace; W representa un átomo de carbono o de nitrogeno; X representa un heteroátomo elegido entre un átomo de oxígeno o un átomo de azufre; R1, R2, R3 y R4 representan, independientemente entre sí, un átomo de hidrogeno, o un grupo alquilo C1-6 o bien, o (i) R1 y R2 pueden formar con el átomo de carbono al que están unidos un grupo cicloalquilo C3-10 y/o (ii) R3 y R4 pueden formar con el átomo de carbono al que están unidos un grupo cicloalquilo C3-10; Y representa un átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-10, cicloalquil C3-10-oxilo, cicloalquil C3-10-alquil C1-6-oxilo, heterocicloalquilalquil C1-6-oxilo, un grupo -COOR1, arilo, arilalquilo, heteroarilo, heterocicloalquilo, ariloxilo, -C(O)-heterocicloalquilo, -C(O)arilo, -CH(OH)arilo, -NH-cicloalquilo estando eventualmente sustituidos dichos grupos con uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo hidroxilo, un grupo alquilo C1-6, alcoxilo C1-6, heterocicloalquilo o un grupo ariloxilo; R representa un átomo de hidrogeno o de halogeno; Z1 está ausente o representa un átomo de azufre, una funcion -NH-, -NHC(O)-, un grupo -S(O)-CH2-, -SCH2-, metileno o un grupo etileno; Z2 está ausente o representa un grupo metileno, un grupo =CH o =C(H)-; Z3 está ausente o representa un átono de oxígeno o un grupo metileno, un =CH o =C(H)-; sabiendo que Z2 solo representa un grupo =C(H)- cuando Z3 está presente y representa un grupo =C(H)-, y a la inversa, formando Z2 y Z3 así un enlace doble; sabiendo que Z2 y Z3, cuando están presentes, pueden estar comprendidos en un grupo cicloalquilo; Z4 es un átomo de hidrogeno, un átomo de carbono que forma eventualmente con un Z3 un grupo cicloalquilo C3-10 cuando Z3 es un grupo =CH, o está ausente, siendo entonces Z3 un grupo =C(H)- que forma un enlace doble con el carbono de ciclohexilo que está adyacente; R5 representa un átomo de hidrogeno o un grupo alquilo eventualmente sustituido con al menos un grupo hidroxilo, heterocicloalquilalquilo C1-6, amina o alquiloxilo, en forma de ácido, de base o de sal de adicion a un ácido o a una base.
ARP100100186A 2009-01-28 2010-01-27 Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros. AR075177A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0900359A FR2941457A1 (fr) 2009-01-28 2009-01-28 Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique
FR0904137A FR2949464B1 (fr) 2009-09-01 2009-09-01 Derives de thiadiazoles et d'oxadiazoles, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR075177A1 true AR075177A1 (es) 2011-03-16

Family

ID=42261833

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100186A AR075177A1 (es) 2009-01-28 2010-01-27 Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros.

Country Status (26)

Country Link
US (1) US8546391B2 (es)
EP (1) EP2391611B1 (es)
JP (1) JP2012516312A (es)
KR (1) KR20110112845A (es)
CN (1) CN102365273A (es)
AR (1) AR075177A1 (es)
AU (1) AU2010209545A1 (es)
BR (1) BRPI1007414A2 (es)
CA (1) CA2750742A1 (es)
CL (1) CL2011001839A1 (es)
CO (1) CO6400221A2 (es)
CR (1) CR20110403A (es)
DO (1) DOP2011000245A (es)
EA (1) EA201170983A1 (es)
EC (1) ECSP11011224A (es)
IL (1) IL214260A0 (es)
MA (1) MA33069B1 (es)
MX (1) MX2011007991A (es)
NI (1) NI201100149A (es)
NZ (1) NZ594244A (es)
PE (1) PE20120362A1 (es)
TN (1) TN2011000353A1 (es)
TW (1) TW201031645A (es)
UY (1) UY32405A (es)
WO (1) WO2010086551A1 (es)
ZA (1) ZA201105525B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963005B1 (fr) * 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
CN102557941B (zh) * 2010-12-07 2015-04-22 成都睿智化学研究有限公司 一种螺环丙基甲酰衍生物的中间体化合物的制备方法
JP6099753B2 (ja) * 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2014060381A1 (de) * 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
CA2931313C (en) 2013-11-21 2022-04-05 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
WO2015106272A1 (en) * 2014-01-13 2015-07-16 Harki Daniel A Small molecule inhibitors of apobec3g and apobec3b
EP3034500A1 (en) * 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
EP3259256B1 (en) * 2015-02-17 2022-03-09 Beijing Erai Therapeutics Co., Ltd. Compounds and methods for inducing browning of white adipose tissue
CN106278895B (zh) * 2015-05-15 2021-07-09 Dic株式会社 羧酸化合物、其制造方法、使用该化合物的液晶组合物
WO2019193540A1 (en) * 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2023060573A1 (en) * 2021-10-15 2023-04-20 Beijing Danatlas Pharmaceutical Co., Ltd. Novel thiadiazolyl derivatives of dna polymerase theta inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
EP1656368A4 (en) * 2002-07-09 2009-08-26 Bristol Myers Squibb Co SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
EP1725231A1 (en) * 2003-12-22 2006-11-29 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivatives as ppar modulators for the treatment of diabetes
GB0427328D0 (en) * 2004-12-14 2005-01-19 Astrazeneca Ab Chemical compounds
GB0511851D0 (en) * 2005-06-11 2005-07-20 Astrazeneca Ab Chemical compounds
EP1893592A1 (en) 2005-06-11 2008-03-05 AstraZeneca AB Oxadiazole derivatives as dgat inhibitors
AU2007236049A1 (en) * 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds

Also Published As

Publication number Publication date
BRPI1007414A2 (pt) 2018-03-06
CA2750742A1 (fr) 2010-08-05
UY32405A (es) 2010-08-31
JP2012516312A (ja) 2012-07-19
AU2010209545A1 (en) 2011-08-18
PE20120362A1 (es) 2012-05-04
CO6400221A2 (es) 2012-03-15
KR20110112845A (ko) 2011-10-13
TW201031645A (en) 2010-09-01
NI201100149A (es) 2011-11-01
CN102365273A (zh) 2012-02-29
MA33069B1 (fr) 2012-02-01
IL214260A0 (en) 2011-09-27
ECSP11011224A (es) 2011-08-31
EP2391611A1 (fr) 2011-12-07
ZA201105525B (en) 2012-12-27
EP2391611B1 (fr) 2014-04-30
NZ594244A (en) 2013-07-26
CR20110403A (es) 2011-09-21
EA201170983A1 (ru) 2012-03-30
US20120040984A1 (en) 2012-02-16
US8546391B2 (en) 2013-10-01
DOP2011000245A (es) 2011-09-15
MX2011007991A (es) 2011-11-18
CL2011001839A1 (es) 2012-01-06
TN2011000353A1 (fr) 2013-03-27
WO2010086551A1 (fr) 2010-08-05

Similar Documents

Publication Publication Date Title
AR075177A1 (es) Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros.
CO6362007A2 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica
CR10643A (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
AR061946A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas, su preparacion y composiciones farmaceuticas
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
MX344927B (es) Composición farmacéutica que contiene derivado de quinolina.
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
CO6351789A2 (es) Derivados de carbamatos de alquiltiazoles, su preparacion y su aplicacion en terapeutica
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
ECSP077215A (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
RS54183B1 (en) PIRAZOLE DERIVATIVES
BRPI1009212B8 (pt) Composto de piperazina capaz de inibir a prostaglandina d sintase, seus usos e composição farmacêutica
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
EA201490722A1 (ru) ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5
CO6460742A2 (es) Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica
MX338631B (es) 5-(fenil/piridinil-etinil)-2-piridina/ 2-pirimidina-carboxamidas como moduladores del receptor de glutamato metabotropico del subtipo 5 (mglur5).
CO6400145A2 (es) Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica
AR049668A1 (es) Proceso quimico para preparar esteres de 4,4 - difluorometil - 3 - oxo - butanoico por reaccion entre una amida y un ester.
ECSP11011196A (es) Derivados de piperidina
AR070910A1 (es) Derivados de sulfonamida sustituida
MY146939A (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
AR088021A1 (es) Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica
PE20090602A1 (es) Nuevos compuestos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal